A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation safeguards at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by activating the mother’s body’s defences to generate protective antibodies, which are then passed to the foetus through the placenta. This mother-derived protection provides newborns with instant defence from the point of delivery, exactly when they are highly susceptible to RSV. The latest research shows that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even shorter intervals between vaccination and birth can still deliver meaningful protection, with evidence suggesting that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst noting that protection can still occur even if given later in the third trimester.
- Nearly 85 per cent protection when immunised 4 weeks before birth
- Maternal antibodies passed through the placenta protect newborns from day one
- Protection achievable with two-week gap before early delivery
- Vaccination in the third trimester still offers significant infant protection
Strong evidence from current research
The efficacy of the pregnancy RSV vaccine has been demonstrated through a comprehensive study conducted across England, reviewing data from approximately 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that six-month timeframe, providing comprehensive and reliable evidence of the vaccine’s actual performance. The study’s findings have been validated by the UK Health Security Agency as showing robust protection for newborns during their most critical early weeks. The breadth of this investigation offers healthcare professionals and parents-to-be with assurance in the vaccine’s established performance across diverse populations and circumstances.
The results reveal a compelling picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV throughout the study period, with the great majority being infants whose mothers did not receive the vaccination. This stark contrast underscores the vaccine’s critical role in preventing serious illness in newborns. The drop in hospital admissions above 80 per cent represents a major public health success, helping to prevent thousands of infants from experiencing the frightening and potentially life-threatening symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research examined birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospital admissions. The sizeable sample and thorough nature of the data gathering ensured that findings were statistically robust and indicative of the general population, rather than isolated cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for best possible protection, as well as to determine whether protection continued to be effective with shorter intervals. The methodology measured practical outcomes rather than controlled laboratory conditions, providing tangible evidence of how the vaccine performs when given across diverse clinical settings and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Understanding RSV and its dangers
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.
The infection produces deep inflammation in the lungs and airways, making it extremely challenging for vulnerable newborns to breathe and feed adequately. Parents often witness their babies visibly struggling, their chests rising whilst they work to get sufficient oxygen into their weakened respiratory system. Whilst the majority of babies recover with clinical support, a modest yet notable number die from respiratory syncytial virus complications each year, making prevention through vaccination a critical public health imperative for defending the youngest and most vulnerable individuals in the population.
- RSV triggers lung inflammation, causing severe breathing difficulties in infants
- Approximately half of newborns catch the virus in their first few months of life
- Symptoms vary between mild colds to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK babies need serious hospital treatment for RSV annually
- Few infants succumb to RSV complications annually in the UK
Adoption rates and expert recommendations
Since the RSV vaccine programme began in 2024, health officials have highlighted the value of pregnant women receiving their jab at the ideal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that timing matters greatly for ensuring newborns receive the strongest possible immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery provides nearly 85% protection, experts recommend women to get their vaccine as soon as feasible from 28 weeks of pregnancy onwards to enhance the antibodies passed to their babies via the placenta.
The messaging from public health bodies remains clear: pregnant women should prioritise vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has reassured expectant mothers that protection is still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those giving birth ahead of schedule. This flexible approach acknowledges the practical demands of pregnancy whilst ensuring strong protection for at-risk infants during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional differences in vaccine uptake
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Certain regions have attained greater immunisation rates among qualifying expectant mothers, whilst others continue working to boost understanding and access to the jab. These regional differences demonstrate variations in medical facilities, communication strategies, and local engagement efforts, though the overall statistics demonstrates consistently strong protection regardless of geographical location.
- NHS trusts launching varied communication campaigns to connect with pregnant women
- Geographic variations in vaccination coverage levels in different parts of England require targeted improvement
- Local healthcare systems adapting programmes to align with local requirements and situations
Real-world impact and parent viewpoints
The vaccine’s impressive effectiveness delivers real advantages for families across the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the introduction of this preventative solution, the 80% decrease in admissions represents thousands of infants spared from severe infection. Parents no longer face the troubling prospect of seeing their babies struggle for breath or labour to feed, symptoms that mark severe RSV infections. The vaccine has fundamentally shifted the landscape of neonatal lung health, offering expectant mothers a preventative option to shield their most at-risk babies during those vital initial period.
For families like that of Malachi, whose serious RSV infection caused devastating brain damage, the vaccine’s availability carries significant emotional significance. His mother’s support of the jab emphasises the profound consequences that preventable illness can cause to young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such grave complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to women in pregnancy navigating their third trimester, changing what was once an unavoidable seasonal threat into a controllable health concern.